Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Dec;18(6):941–946. doi: 10.1111/j.1365-2125.1984.tb02567.x

Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.

I H Benedek, R A Blouin, P J McNamara
PMCID: PMC1463695  PMID: 6529534

Abstract

Serum protein and lipid concentrations as well as the serum protein binding of propranolol, diazepam and phenytoin were measured in normal weight and obese volunteers. Concentrations of alpha 1-acid glycoprotein (AAG) in the obese subjects were double that of the lean controls. Conversely, concentrations of high density lipoproteins (HDL) were decreased in the obese group. The serum binding of propranolol was increased in the obese subjects and correlated with serum AAG concentrations. Diazepam binding was slightly decreased in the obese as a result of lower serum albumin concentrations and elevated free fatty acids. The binding of phenytoin was comparable in all of the volunteers. These findings point out some of the complex pathophysiologic changes associated with obesity which may in turn influence drug disposition and hence drug therapy in the obese patient.

Full text

PDF
941

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R., Greenblatt D. J., Divoll M., Harmatz J. S., Shader R. I. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther. 1981 Jun;217(3):681–685. [PubMed] [Google Scholar]
  2. Abernethy D. R., Greenblatt D. J., Divoll M., Shader R. I. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci. 1982 Aug;71(8):942–944. doi: 10.1002/jps.2600710827. [DOI] [PubMed] [Google Scholar]
  3. Abernethy D. R., Greenblatt D. J. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet. 1982 Mar-Apr;7(2):108–124. doi: 10.2165/00003088-198207020-00002. [DOI] [PubMed] [Google Scholar]
  4. BILLEWICZ W. Z., KEMSLEY W. F., THOMSON A. M. Indices of adiposity. Br J Prev Soc Med. 1962 Oct;16:183–188. doi: 10.1136/jech.16.4.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benedek I. H., Fiske W. D., 3rd, Griffen W. O., Bell R. M., Blouin R. A., McNamara P. J. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol. 1983 Dec;16(6):751–754. doi: 10.1111/j.1365-2125.1983.tb02258.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gordon T., Castelli W. P., Hjortland M. C., Kannel W. B., Dawber T. R. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study. Ann Intern Med. 1977 Oct;87(4):393–397. doi: 10.7326/0003-4819-87-4-393. [DOI] [PubMed] [Google Scholar]
  7. Hron W. T., Menahan L. A. A sensitive method for the determination of free fatty acids in plasma. J Lipid Res. 1981 Feb;22(2):377–381. [PubMed] [Google Scholar]
  8. Jackson P. R., Tucker G. T., Woods H. F. Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther. 1982 Sep;32(3):295–302. doi: 10.1038/clpt.1982.163. [DOI] [PubMed] [Google Scholar]
  9. Kannel W. B., Gordon T., Castelli W. P. Obesity, lipids, and glucose intolerance. The Framingham Study. Am J Clin Nutr. 1979 Jun;32(6):1238–1245. doi: 10.1093/ajcn/32.6.1238. [DOI] [PubMed] [Google Scholar]
  10. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  11. Piafsky K. M., Borgá O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978 Dec 28;299(26):1435–1439. doi: 10.1056/NEJM197812282992604. [DOI] [PubMed] [Google Scholar]
  12. Ricca G. A., McLean J. W., Taylor J. M. Kinetics of induction of alpha 1-acid glycoprotein. Ann N Y Acad Sci. 1982;389:88–105. doi: 10.1111/j.1749-6632.1982.tb22127.x. [DOI] [PubMed] [Google Scholar]
  13. Ridd M. J., Brown K. F., Moore R. G., McBride W. G., Nation R. L. Diazepam plasma binding in the perinatal period: influence of nonesterified fatty acids. Eur J Clin Pharmacol. 1982;22(2):153–160. doi: 10.1007/BF00542461. [DOI] [PubMed] [Google Scholar]
  14. Routledge P. A., Shand D. G., Barchowsky A., Wagner G., Stargel W. W. Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction. Clin Pharmacol Ther. 1981 Aug;30(2):154–157. doi: 10.1038/clpt.1981.141. [DOI] [PubMed] [Google Scholar]
  15. Tozer T. N., Gambertoglio J. G., Furst D. E., Avery D. S., Holford N. H. Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci. 1983 Dec;72(12):1442–1446. doi: 10.1002/jps.2600721218. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES